

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 16, No. 14

July 28th, 2017

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association* and membership news. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- CY2018 *Physician Fee Schedule*
- ANCO's 2017 *Professional Education Meeting*
- ANCO's 3Q2017 *Hematologic Malignancies Updates*

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members.

The next regular *ANCO FAX News* will be published on August 11th. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; execdir@anco-online.org.

The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!

- Physician Members
- Nurses & Office Managers
- Office Staff
- Colleagues & Representatives

The *Association of Northern California Oncologists* (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge.

The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

CMS has released its proposed CY2018 Physician Fee Schedule (PFS) and Outpatient Prospective Payment System (OPPS) rules. Read the proposed rule at www.federalregister.gov/documents/2017/07/20/2017-14883/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment; read the fact sheet at www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2017-Fact-Sheet-items/2017-07-13.html. Major changes include a reduction in payments to hospitals participating in 340B under OPPS. Overall, physician payment rates will increase by .31% in CY2018 compared to CY2017, including an estimated 1% increase for radiation oncology. Read Bobbi Buell's summary of the proposed rule at www.anco-online.org/BBMPFS2018Analysis.pdf. ACCC will host a webinar entitled *What You Need to Know About CMS' Proposed 2018 OPPS and PFS Rules* on August 9th at 1PM PT. Register at register.gotowebinar.com/register/701021510179755009.

In a statement submitted to a House Energy and Commerce Health Subcommittee hearing entitled *Examining Bipartisan Legislation to Improve the Medicare Program*, ASCO expressed strong support for two pieces of legislation that aim to strengthen Medicare—HR849, *Protecting Seniors' Access to Medicare Act of 2017*, and HR3120. HR849 would repeal the *Independent Payment*

Advisory Board, a group created by the ACA to reduce Medicare spending growth. HR3120 would remove a requirement that EHR standards become more stringent over time. Read ASCO's statement at www.asco.org/advocacy-policy/asco-in-action/asco-supports-bills-improve-medicare-comments-house-energy-and.

ASCO has issued a position statement aimed at contributing to the national dialogue on rising drug prices. The statement, which asserts that any solutions must also preserve patients' access to care and foster innovation, analyzes a wide array of options and recommends that a panel of stakeholders be established to determine which proposals will be effective and develop a uniform approach for assessing the value of drugs. The ASCO position statement highlights that new cancer drugs routinely cost more than \$100,000 per year, and prices on many existing treatments continue to rise, causing serious financial hardship even for many patients with insurance. Drugs are the fastest growing component of cancer care costs, which are expected to increase by more than 25% between 2010 and 2020. Read ASCO's statement at www.asco.org/advocacy-policy/asco-in-action/asco-offers-path-addressing-affordability-cancer-drugs-new-position?

CMS is readying a fraud prevention initiative that removes *Social Security Numbers* from Medicare cards to help combat identity theft and safeguard taxpayer dollars. The new cards will use a unique, randomly-assigned number called a *Medicare Beneficiary Identifier* (MBI) to replace the *Social Security-based Health Insurance Claim Number* (HICN) currently used on the Medicare card. CMS will begin mailing new cards in April 2018. For more information, visit the CMS *Social Security Removal Initiative* (SSNRI) website at www.cms.gov/medicare/ssnri/.

The Medicare Quality Payment Program (QPP), established by the *Medicare Access and CHIP Reauthorization Act* (MACRA), began on January 1st. This year is a transition year meaning you can

“pick your pace” when implementing QPP in your practice. CMS has posted new resources to the QPP website to help clinicians successfully participate in the first year of the QPP. The new resources focus on support for small practices and alternative payment models (APMs). Visit qpp.cms.gov for more information.

CMS has issued a proposed rule that would make changes in the second year of the QPP. The proposed rule “aims to simplify the program, especially for small, independent, and rural practices.” Read the CMS fact sheet at www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Value-Based-Programs/MACRA-MIPS-and-APMs/Proposed-rule-fact-sheet.pdf; read ASCO’s summary at www.asco.org/advocacy-policy/asco-in-action/proposed-2018-qpp-rule-adds-flexibility-questions-medicare-part-b; and, read Bobbi Buell’s analysis at www.anco-online.org/BBMIPS2018.pdf.

Unsure of your MIPS participation status? Clinicians can now use an interactive tool on the CMS *Quality Payment Program* website to determine if they should participate in MIPS. Visit qpp.cms.gov > Check Now, enter your NPI and information will then be provided on whether or not you should participate in MIPS in 2017 and where to find resources.

CMS is encouraging physicians to sign up for the new CMS QPP listserv to stay up-to-date on new resources, upcoming milestones and deadlines, and CMS webinars on the QPP. To subscribe to the QPP listserv, go to qpp.cms.gov and select “Subscribe to Email Updates” at the bottom of the page.

ASCO is pleased to announce that its *Quality Oncology Practice Initiative (QOPI) Qualified Clinical Data Registry (QCDR)* is now available for CMS MIPS reporting effective July 1st. By using the QOPI QCDR for MIPS reporting, practices will be able to report on one measure for one patient in 2017 to avoid cuts to Medicare reimbursements in 2019. Express your interest in

participating in the QOPI QCDR by e-mailing qopi@asoc.org. Once registration is officially open, practices will be contacted regarding the necessary steps to begin their on-boarding process. For more information, please visit www.instituteforquality.org/qopi/about/quality-reporting.

ASCO’s series of webinars to guide oncology practices to successful quality reporting are available at www.asco.org/macra > MACRA Webinar Series. ASCO has developed a MACRA decision tree tool to help oncology practices find precise information on their QPP participation status at www.asco.org/practice-guidelines/billing-coding-reporting/macra-quality-payment-program/macra-practice-tools/determine-status. For more information and access to ASCO’s revamped QPP/MACRA toolkit, educational materials, and resources, go to www.asco.org/macra. ASH’s updated MACRA webpage is at www.hematology.org/Clinicians/7427.aspx.

The *American Medical Association (AMA)* has produced a new short video entitled *One Patient, One Measure, No Penalty: How to avoid a Medicare payment penalty with basic reporting*. The video and other AMA resources are available at www.ama-assn.org/qpp-reporting.

CMA’s *Center for Economic Services (CES)* has published an update to its MACRA preparation checklist entitled *MACRA: What Should I Do Now to Prepare?* available at www.cmanet.org/macra.

CMA, MOASC, and State Legislative & Regulatory Issues

Sacramento can be a dangerous place for doctors. Many bills impacting medicine wind their way through the *Capitol* on their journey to the *Governor’s* desk. And, many of these bills threaten the medical profession with the backing of powerful lobbyists and PACs. It’s critical that **physicians have an advocate at work for them every day and who knows how to speak on their behalf. That advocate is the *California Medical***

Association (CMA). While physicians keep a close eye on their patients, CMA is keeping a close eye on those bills...and more. **Got payment delays? Feeling victimized by payers and overwhelmed by the process? Don't let the health plans mistreat you.** The CMA's *Center for Economic Services (CES)* has a team of reimbursement specialists available to assist ANCO's CMA members experiencing payment problems with third-party payers. For membership, please call (916) 551-2042; for reimbursement assistance, please call CMA's *Reimbursement Helpline* at (888) 401-5911.

CMA Practice Resources (CPR) is a monthly e-mail bulletin from CMA's *Center for Economic Services* that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit www.cmanet.org/cpr to subscribe.

Noridian/JEMAC, DHCS/MediCal, & Private Payers

Noridian Administrative Services is the **Jurisdiction E (JE) Medicare Administrative Contractor (MAC).** Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews *Announcements*—New Medicare Cards with New Numbers: 3 Changes You May Need to Make; Quality Payment Program: View Recent Webinar Recordings; Hospice Quality Reporting Program: Non-Compliance Letters; SNF Quality Reporting Program: Non-Compliance Letters; Billing for Stem Cell Transplants; Quality Payment Program: Explanation of Special Status Calculation; Updated CMS Measures Inventory

Posted

Claims, Pricers, and Codes—ICD-10-CM Errata Available; Clinicians: Medicare Part B Crossover Claims Issue Tied to Error Code H31312

Publications—CLIA Webcast: Audio Recording and Transcript-New; Appeals Call: Audio Recording and Transcript-New; Suite of Products & Resources for Billers & Coders Educational Tool-Reminder; Quality Payment Program Listening Session: Audio Recording and Transcript-New; Chronic Care Management Services Fact Sheet-Reminder; Quality Payment Program 2017 MIPS: Improvement Activities Performance Category Web-Based Training Course-New

- Redetermination Requests Which Contain Multiple ICNs
- July Webinars-Register Now
- Medicare After Hours-Evening Webinars Available for Your Professional Growth
- Pegfilgrastim (Neulasta) J2505-R2
- Positron Emission Tomography Scans Coverage-R10
- Flow Cytometry LCD-R7
- NCCI PTP Edits-Version 23.3 Effective October 1, 2017 CR10183
- Internet-based PECOS Help is Available

Noridian/JEMAC's Electronic Data Interchange Support Services (EDISS) invites you to subscribe to its e-mail distribution list to receive current information at www.edissweb.com/cgp/news/index.html.

Forthcoming *Noridian/JEMAC* meetings/webinars/workshops include:

- Self Service Reopenings in NMP for Part B Providers (August 8)

Visit med.noridianmedicare.com/web/job/education/training-events for more information and to register.

Earlier this month, the *Department of Health Care Services* (DHCS) notified approximately 30,000 MediCal providers that they were being deactivated because they had not submitted a claim or rendered services reported on a MediCal claim in the last 12 months. DHCS has, however, decided to not proceed with the planned deactivation. Instead, DHCS will be reconsidering what is defined as inactivity after DHCS was made aware that such deactivation would be problematic for some providers.

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

ANCO's 2017

Professional Education Meeting

ANCO will host its 2017 professional education meeting on September 6th at the *San José Fairmont*. The agenda will include *QPP/MACRA*, *ASCO's COME HOME Project*, *USP797/800*, and *California Legislative/Regulatory Updates*. Download the meeting announcement at www.anco-online.org/ProfEduc2017.pdf.

ANCO's 2017 Hematologic Malignancies Updates

ANCO is organizing a series of *Hematologic Malignancies Updates* in 2017. The second *Update* takes place on September 9th at the *Stanford Park Hotel* with Bruno Medeiros, M.D., *Stanford University*, Charalambos Andreadis, M.D., *University of California, San Francisco*, and Brian Sworder, M.D., *Stanford University*. The latest research on novel treatment modalities for leukemias and lymphomas, along with case studies for these diagnoses will be presented. These updates are supported by *Janssen Biotech*, *Merck*, *Pfizer Oncology*, and *Pharmacyclics*. Download the meeting announcement at www.anco-online.org/3Q2017HemeMalig.pdf.

SAVE THE DATE

18th Multidisciplinary Management of Cancers: A Case-based Approach

The 18th *Multidisciplinary Management of Cancers: A Case-based Approach* returns to the *Silverado Resort and Spa* in Napa on March 16-18th. The meeting is sponsored by the *Association of Northern California Oncologists*, *Stanford Cancer Institute*, *UC Davis Comprehensive Cancer Center*, and the *UCSF Helen Diller Family Comprehensive Cancer Center*. Go to www.multicancers.org to register your interest in receiving registration and housing information when it becomes available in the Fall.

Additional Education Meetings

August 11th

Treatment Update for Adults Living with Acute Lymphocytic/Lymphoblastic Leukemia (ALL)
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

September 8-9th

2017 ASH Meeting on Hematologic Malignancies
ASH
Chicago
(www.hematology.org/Malignancies/Registration.aspx)

September 24-27th

59th Annual Meeting
ASTRO
San Diego
(www.astro.org)

September 27-28th

ASCO Advocacy Summit 2017: Lead, Engage, Influence
ASCO
Alexandria
(www.surveymonkey.com/r/AdvocacySummit2017)

October 6-7th

12th Annual Congress: Hematologic Malignancies
NCCN
San Francisco
(<https://www.nccn.org/professionals/meetings/he>)

matological/default.aspx)

Please contact the ANCO office for more information about these meetings.

ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

[Editor's Note: All ANCO members are also eligible for several tangible benefits.]

Board of Directors

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The **next regularly scheduled ANCO Board of Directors meeting is scheduled for September 26th**. Please call José Luis González, *ANCO Executive Director*, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

Congratulations to ANCO member David Oh, M.D., *University of California, San Francisco*, for receiving an ASCO *Young Investigator Award* for 2018 at ASCO's 2017 Annual Meeting.

The *Conquer Cancer Foundation* (CCF) of the *American Society of Clinical Oncology* (ASCO) is now accepting applications for the 2018 *Young Investigator Award* (YIA). The *Association of Northern California Oncologists* (ANCO) is funding one 2018 YIA for a qualified northern California applicant, and urges all eligible northern California physicians to apply. The YIA is a one-year, \$50,000 grant that provides research funding to promising physicians to support their transition from final years of training to faculty appointment and to encourage and promote quality research in clinical oncology. Applications in all areas of cancer research are accepted from U.S. and international applicants. For 2018, CCF has dedicated funding for the following areas: breast cancer, northern California researchers, global oncology, kidney cancer, lung

cancer, pediatric cancer, sarcoma, and supportive care. Other areas of interest include cholangiocarcinoma, chronic lymphocytic leukemia, gynecological cancers, and melanoma. YIA applications opened on July 1st and are due by 11:50PM ET on September 21st. Eligibility criteria, award details, and the request for proposals are available on the CCF website (www.conquer.org/young-investigator-award). For questions about the YIA or assistance with your application, please e-mail grants@conquer.org.

ASCO urges community oncologists to join ASCO's Leadership Development Program.

Participants in this year-long leadership program will gain extensive exposure to the roles and mission of ASCO, its leadership, and the *Society's* powerful place in developing the future of cancer care. Visit www.asco.org/training-education/professional-development/leadership-development-program for more information and to apply.

A current *Directory of Members* is available online at www.anco-online.org/pubs.html as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at execdir@anco-online.org with any corrections, additions, and/or deletions.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Diablo Valley Oncology & Hematology Medical Group*, *EPIC Care*, *Marin Cancer Care*, *Pacific*

Cancer Care, and *Palo Alto Medical Foundation* for their multi site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

AbbVie • Agendia • Alexion Pharmaceuticals
AMGEN • ARIAD Pharmaceuticals
Astellas Oncology • AstraZeneca
Bayer Healthcare Pharmaceuticals
bioTheranostics
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Cardinal Health Specialty Solutions
Celgene • Clovis Oncology • Daiichi Sankyo
Eisai • EMD Serono • Exelixis
Foundation Medicine • Genentech BioOncology
Genomic Health • Gilead Sciences
Guardant Health • Helsinn Oncology
Heron Therapeutics • Incyte
Janssen Oncology • Jazz Pharmaceuticals
Kite Pharmaceuticals • Lilly Oncology • Merck
nanoString • Novartis Oncology
Oncology Supply/ION • Pfizer Oncology
Pfizer US Biosimilars • Pharmacyclics
Sandoz Biopharmaceuticals • Sanofi Genzyme
Seattle Genetics • Taiho Oncology
Takeda Oncology • Tesaro • TEVA Oncology

We especially wish to thank and welcome *Agendia, bioTheranostics, EMD Serono, Kite Pharmaceuticals*, and *Pfizer US Biosimilars* as new Corporate Members for 2017. *Dendreon, Genoptix Medical Laboratory, GenPath Oncology, Infinity Pharmaceuticals, Ipsen Biopharmaceuticals, Medivation, Merrimack Pharmaceuticals*, and *Prometheus Laboratories* did not renew their memberships for 2017. Please visit www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

AMGEN informs ANCO that the *United States Food and Drug Administration* has approved Blincyto to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children.

Bristol-Myers Squibb Oncology informs ANCO that the *United States Food and Drug Administration* has expanded the indication for Yervoy to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.

Merck informs ANCO that the *United States Food and Drug Administration* has approved a new formulation of Emend for injection that has a lower concentration of edetate disodium (EDTA), an inactive ingredient. The new formulation (5.4mg EDTA, NDC 0006-3061-00) will replace the existing formulation (18.8mg EDTA, NCD0006-3941-32).

Clinical Trial News

Stanford Cancer Center brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients

with Unresectable Locally Advanced or Metastatic Melanoma (MELMTS0006; NCT02908672).

Principal Investigator: Sunil Reddy, MD;
Contact: Phuong Pham, (650) 725-9810,
ppham5@stanford.edu.

- A Randomized, Controlled, Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma (SKIN0036; NCT02678572). Principal Investigator: Sunil Reddy, MD; Contact: Phuong Pham, (650) 725-9810, ppham5@stanford.edu.

- Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib (BMT316; NCT02869633). Principal Investigator: David Miklos, MD; Contact: Kelly Chyan, (650) 625-8130, kchyan@stanford.edu.

- Radical RADiotherapy and Immunotherapy for Metastatic Cancer of the Lung (RRADICAL; LUN0088; NCT03176173). Principal Investigator: Michael Gensheimer, MD; Contact: Samantha Wong, (650) 498-8495, swong8@stanford.edu.

- Home or Away From Home: Comparing Patient and Caregiver Reported Quality of Life (QoL) and Other Patient-centered Outcomes for Inpatient Versus Outpatient Management of Neutropenia in Children With AML (Age Range: 0 to 18 years; PEDSHEMAML0001; NCT02777021). Principal Investigator: Catherine Aftandilian, MD; Contact: Nancy Sweeters, (650) 721-4074, nks2016@stanford.edu.

- A Phase I/II Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors (RENAL0035; NCT02771626). Principal Investigator: Alice Fan, MD; Contact: Shermeen Poushnejad, (650) 724-7662, shermeen@stanford.edu.

- A Phase I, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients with Unresectable or Metastatic B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Expresses B7-H3 (VAR0148; NCT02628535). Principal Investigator: Shivaani Kummer, MD; Contact: Marina Karmanova, (650) 721-4083, mkarma@stanford.edu.

- MR Imaging of Inflammatory Responses in the Central Nervous System with Ferumoxytol-Enhanced MRI (Pediatric Brain Tumor Protocol, Age Range 2 years and beyond; PEDSBRNCNS0008; NCT03179449). Principal Investigator: Michael Iv, MD; Contact: Paymon Rezaii, (650) 743-8336, prezaii@stanford.edu.

- A Study of Escalating Doses of ASG-22CE Given as Monotherapy I Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 (BLDR0024; NCT02091999). Principal Investigator: Sandhya Srinivas, MD; Contact: Denise Haas, (650) 723-1252, dhaas@stanford.edu

Further information is available at cancer.stanford.edu/trials/.

UC Davis's portfolio of Phase I clinical trials is available online at www.anco-online.org/UCDP1Availability.xlsx.

UC San Francisco brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- A Phase I, Multicenter, Open-Label Study of Oral Entrectinib (RXDX-101) in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2, NTRK3, ROS1 or ALK Molecular Alterations (CC#17951). Principal Investigator: Contact: Claire Hooker, (415) 885-3724, claire.hooker@ucsf.edu

- A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinoma (CC#169524). Principal Investigator: Contact: Claire Hooker, (415) 885-3724, claire.hooker@ucsf.edu

Further information is available at cancer.ucsf.edu/trials.

Publications, Resources, Services, & Surveys

ANCO encourages all members to participate in ASCO's *Practice Census*, the only annual survey of the entire oncology community that aims to capture and describe changes in cancer care and oncology practice over time. Be counted by going to apps.asco.org/oncology-practice-central/survey.

The ASCO Guidelines App is your go-to tool for implementing guideline recommendations into

practice. This user-friendly app provides health care providers, patients, and caregivers with the recommended cancer care options for a variety of cancer types. It also includes interactive tools to inform treatment decisions at the point of care, thus increasing the quality of care provided to patients. The app is free to members and nonmembers, kept up to date and will continue to grow as more guidelines and tools are added. Download the app at www.asco.org/guidelines or www.asco.org/apps.

ASCO's Clinical Affairs Department is dedicated to providing services, education, and resources to support oncology practices. It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit www.asco.org/practice-guidelines/practice-support.

ASCO has issued a focused guideline update on the use of biomarkers in women with early breast cancer. The update provides evidence-based recommendations on the use of the MammaPrint genomic test in guiding decisions on adjuvant systemic therapy. Read the update at www.asco.org/practice-guidelines/quality-guidelines/guidelines/assays-and-predictive-markers.

ASCO is launching its new Practice Engagement Program to help administrators, physicians, and other members of the care team navigate ASCO tools, programs, and resources available to help oncology practices respond to the changes occurring in the cancer care delivery system. Building on an array of resources developed to help practices remain viable and thrive during this turbulent period, the new *Practice Engagement Team* will help participating practices learn more about the specific ASCO services and

programs that can best support their needs. Learn more at www.asco.org/advocacy-policy/asco-in-action/new-practice-engagement-program-connects-practices-specific-resources.

ASCO's PracticeNET is a collaborative network in which practices share and receive insights to enhance their business operations and quality of care. PracticeNET is the first initiative of ASCO's *Clinical Affairs Department*. This new initiative uses existing data from your practice management system to offer customizable reports that measure practice-wide and individual performance against a national database of other PracticeNET participants. Go to www.asco.org/PracticeNET for more information.

The July 2017 issue of ASCO's Journal of Oncology Practice (JOP) is available online and features articles entitled *Financial Impact of Cancer Drug Wastage and Potential Cost Savings from Mitigation Strategies*; *Design Challenges of an Episode-Based Payment Model in Oncology: The Centers for Medicare & Medicaid Services Oncology Care Model*; *Pursing Value in Cancer Care: A Model in Progress*. Visit jop.ascopubs.org for more information.

ASCO and Innovative Oncology Business Solutions (IOBS) have announced a new collaboration, ASCO COME HOME—an oncology medical home program designed to transition community oncology practices from volume-based to value-based care by structuring reimbursement around the full range of services needed by patients with cancer. ASCO COME HOME will also prepare oncology practices for full implementation of the Quality Payment Program under MACRA. ASCO is currently accepting practices for the fee-based program. For more information, please visit www.asco.org/practice-guidelines/practice-support/asco-consulting-services/asco-come-home.

The July/August issue of ACCC's Oncology Issues includes articles entitled *A Cognitive Approach to Cancer Treatment*; and, *Normalizing Feelings of Grief & Loss in Oncology Nurses*. Visit www.accc-

cancer.org/oncology_issues to read this issue.

ACCC's online *Oncology Drug Database* provides quick access to information on oncology drug coding, billing, and reimbursement at www.accc-cancer.org/drugdatabase/.

ACCC's enhanced set of *Financial Advocacy Network* resources are at www.accc-cancer.org/resources/FinancialAdvocacy-Overview.asp. This "one-stop" destination for comprehensive financial advocacy information includes online training materials, practical financial advocacy tools, peer-to-peer networking, and more.

The cost of cancer care continues to be a top concern for patients and their healthcare providers. In response, ACCC has launched *The Financial Advocacy Boot Camp*, the first free online training program designed for all those who work to assist cancer patients in navigating financial issues related to their cancer treatment. Learn more at www.accc-cancer.org/resources/FinancialAdvocacy-bootcamp.asp.

Read four perspectives—from a physician, a patient advocate, a payer, and industry—on *How Should We Intervene on the Financial Toxicity of Cancer Care?* at connection.asco.org/magazine/current-controversies-oncology/how-should-we-intervene-financial-toxicity-cancer-care.

ACCC's 2017 *Patient Assistance and Reimbursement Guide* is an essential tool for cancer program staff to use in helping patients with issues related to the cost of treatment and in meeting reimbursement challenges. The *Guide* features a list of pharmaceutical and non-pharmaceutical patient assistance programs (PAPs), including directions on how to apply and links to enrollment forms. Visit www.accc-cancer.org/publications/pdf/Patient-Assistance-Guide-2017.pdf to access this resource. In addition, ACCC has developed a tool for accessing patient assistance and reimbursement programs for use on a desktop, table, or mobile device. The *Financial Advocacy Network* (FAN) app is available at accc-fan-app.org. *assistPoint* is

your website for complimentary one-stop cancer Patient Assistance. You can search by generic, brand name, manufacturer, or diagnosis for the enrollment forms you need; get enrollment form PDFs for cancer drugs; get NDC numbers for all of those drugs; find the HCPCS J-code for each drug; get coding and billing guidelines for many drugs; and, learn more about the drugs you give. Go to www.assistpoint.com to learn more.

NCCN has published and/or updated their *Chemotherapy Order Templates, Clinical Practice Guidelines in Oncology, Drugs & Biologics Compendium, Evidence Blocks, Guidelines for Patients, Imaging Appropriate Use Criteria, and/or Radiation Therapy Compendium* for chronic myeloid leukemia (V1.2018), Hodgkin lymphoma (V1.2017), malignant pleural mesothelioma (V2.2017), melanoma (chemotherapy order template), neuroendocrine tumors of the pancreas (V3.2017), non-small cell lung cancer (V8.2017), uterine neoplasms (V3.2017). Go to www.nccn.org for more information. NCCN is pleased to offer pocket-sized versions of the NCCN *Clinical Practice Guidelines in Oncology* for a number of their guidelines at www.nccn.org/redirects/nicelines.asp?Type=general.